This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Artz A, Pollyea D, Kocherginsky M, Stock W, Rich E, Odenike O et al. Performance status and comorbidity predict transplant related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 954–964.
van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5728–5738.
Michaelis L, Sher D, Myers M, Siddiqui M, Collins-Jones D, Ulaszek J et al. Prognostic significance of WT-1 levels in patients with myelodysplastic syndrome and leukemia after reduced-intensity allogeneic transplantation [abstract]. Proc Am Soc Clin Oncol 2006; 24: 6524a.
Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H et al. Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. Blood 2005; 105: 3035–3041.
Huisman C, De Weger RA, Devries L, Tilanus MLJ, Verdonck LF . Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant 2007; 39: 285–291.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Michaelis, L., Lin, S., Joseph, L. et al. Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant 40, 181 (2007). https://doi.org/10.1038/sj.bmt.1705707
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705707
This article is cited by
-
Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation
Leukemia (2012)
-
Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative
Bone Marrow Transplantation (2008)
-
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2007)